



NEULAND LABORATORIES LIMITED

Flat No.204, II Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad-500 016. A.P., INDIA.
Phone : +91-40-30211600, 23412934, 66518682. Fax : +91-40-23412957
E-mail : neuland@neulandlabs.com URL : www.neulandlabs.com

February 10, 2012

The National Stock Exchange Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E)
Mumbai – 400 001

Scrip Code: NEULANDLAB
Series: EQ

Dear Sirs,

Unaudited Financial Results

This is to inform you that the Board of Directors at its meeting held today, i.e., February 10, 2012 have approved the unaudited financial results for the quarter ended December 31, 2011. A copy of the same is enclosed. This information has been sent to you on cnlist@nse.co.in.

This is for your information and records.

Thanking you,

Yours Sincerely
For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Encl: a/a



NEULAND LABORATORIES LIMITED

Flat No.204, II Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad-500 016. A.P., INDIA.

Phone : +91-40-30211600, 23412934, 66518682. Fax : +91-40-23412957

E-mail : neuland@neulandlabs.com URL : www.neulandlabs.com

NEULAND LABORATORIES LIMITED

Registered Office : 204, Meridian Plaza, Ameerpet, Hyderabad - 500016

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2011

Amount in ₹ Lacs, except share data

Sl. No.	Particulars	Quarter Ended 31.12.2011 (Unaudited)	Quarter Ended 30.09.2011 (Unaudited)	Quarter Ended 31.12.2010 (Unaudited)	Nine Months Ended 31.12.2011 (Unaudited)	Nine Months Ended 31.12.2010 (Unaudited)	Year Ended 31.03.2011 (Audited)
1	(a) Net Sales / Income from Operations	10,816.17	12,227.66	9,534.16	33,275.04	28,478.07	39,357.23
	(b) Other Operating Income	205.69	102.53	148.91	473.04	257.57	424.21
	Total Income	11,021.86	12,330.19	9,683.07	33,748.08	28,735.64	39,781.44
2	Expenditure						
	(a) (Increase) / Decrease in stock in trade and work in progress	(53.31)	(43.92)	262.95	(723.43)	(5.44)	(317.19)
	(b) Consumption of Raw Materials	6,675.63	7,953.59	5,502.99	22,101.16	17,972.67	25,308.09
	(c) Employees Cost	897.95	646.69	644.48	2,204.25	1,937.69	2,606.03
	(d) Depreciation	382.80	367.44	390.17	1,115.39	1,155.86	1,541.12
	(e) Manufacturing Expenses	1,033.31	1,027.99	856.83	2,903.99	2,487.42	3,335.09
	(f) Administration, Selling and Other Expenses	1,140.48	1,259.98	860.71	3,257.51	2,915.98	3,998.75
	Total Expenditure	10,076.86	11,211.77	8,518.13	30,858.87	26,464.18	36,471.89
3	Profit from Operations before Foreign Exchange (gain) / loss and Interest (1-2)	945.00	1,118.42	1,164.94	2,889.21	2,271.46	3,309.55
4	Foreign Exchange (gain) / loss (Net) (Refer Note 5)	445.34	378.82	(8.34)	790.48	(172.64)	(145.78)
5	Profit from Operations before Interest (3-4)	499.66	739.60	1,173.28	2,098.73	2,444.10	3,455.33
6	Interest (Net)	839.69	865.36	757.38	2,478.61	2,216.44	2,983.71
7	Profit / (Loss) before Tax (5-6)	(340.03)	(125.76)	415.90	(379.88)	227.66	471.62
8	Tax Expense						
	(a) Current tax	-	-	44.93	17.19	44.93	94.00
	(b) Deferred Tax	-	-	21.00	-	21.00	-
	(c) MAT Credit entitlement	-	-	(44.93)	(17.19)	(44.93)	(94.00)
	(d) Excess provision of income tax no longer required	-	-	-	-	-	(37.39)
	(e) Wealth Tax	-	-	-	-	-	2.11
9	Net Profit / (Loss) for the period (7-8)	(340.03)	(125.76)	394.90	(379.88)	206.66	506.90
10	Paid-up Equity Share Capital (Face Value ₹10 per share)	546.71	546.71	546.71	546.71	546.71	546.71
11	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						6,646.17
12	Earnings per Share (EPS) (in ₹)						
	(a) Basic	(6.30)	(2.33)	7.32	(7.04)	3.83	9.39
	(b) Diluted	(6.29)	(2.33)	7.30	(7.03)	3.82	9.38
13	Public Shareholding						
	(a) Number of Shares	3,582,343	3,582,343	3,359,633	3,582,343	3,359,633	3,444,717
	(b) Percentage of Shareholding	66.38%	66.38%	62.25%	66.38%	62.25%	63.83%
14	Promoters and Promoter Group Shareholding						
	(a) Pledged / Encumbered						
	-Number of Shares	551,000	488,000	200,000	551,000	200,000	200,000
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	30.37%	26.90%	9.82%	30.37%	9.82%	10.25%
	-Percentage of Shares (as a % of the total share capital of the Company)	10.21%	9.04%	3.71%	10.21%	3.71%	3.71%
	(b) Non-encumbered						
	-Number of Shares	1,263,112	1,326,112	1,836,822	1,263,112	1,836,822	1,751,738
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	69.63%	73.10%	90.18%	69.63%	90.18%	89.75%
	-Percentage of Shares (as a % of the total share capital of the Company)	23.41%	24.58%	34.04%	23.41%	34.04%	32.46%

DR Rao

Works : (i) Bonthapalli (V), Veerabhadraswamy Temple Road, Jinnaram (M). Medak Dist. 502 313, A.P., INDIA

(ii) Plot Nos. 92.93.94.257.258.259, IDA, Pashamylaram, Isnapur, Patancheru (M). Medak Dist. 502 319, A.P., INDIA



NEULAND LABORATORIES LIMITED

Flat No.204, II Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad-500 016. A.P., INDIA.

Phone : +91-40-30211600, 23412934, 66518682. Fax : +91-40-23412957

E-mail : neuland@neulandlabs.com URL : www.neulandlabs.com

Amount in ₹ Lacs

SEGMENT INFORMATION UNDER CLAUSE 41 OF THE LISTING AGREEMENT						
SEGMENT REVENUE (NET SALES)						
(a) India	1,931.89	2,392.10	1,719.13	6,258.30	5,231.62	7,560.54
(b) Other than India	8,884.28	9,835.56	7,815.03	27,016.74	23,246.45	31,796.69
Total	10,816.17	12,227.66	9,534.16	33,275.04	28,478.07	39,357.23

NOTES:

- 1 The above unaudited financial results which have been subjected to a Limited Review by Statutory Auditors, were reviewed by the Audit Committee at their meeting held on February 9, 2012, and approved and taken on record at the Board of Directors meeting held on February 10, 2012.
- 2 There was one investor complaint pending at the beginning of the quarter. Two investor complaints were received during the quarter and all the three complaints were disposed off during the quarter. There were no investor complaints pending at the end of the quarter.
- 3 EPS for the quarters and nine months is not annualised.
- 4 The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- 5 The Foreign Exchange (Gain) / Loss (net) includes unrealised loss on forward contracts of ₹269.36 lacs for the quarter ended December 31, 2011, ₹253.53 lacs for the quarter ended September 30, 2011, ₹(4.85) lacs for the quarter ended December 31, 2010, ₹522.90 for the nine months ended December 31, 2011, ₹(27.45) lacs for the nine months ended December 31, 2010, ₹NIL for the year ended March 31, 2011.
- 6 The Employee's Cost under 2(c) above for the quarter includes ₹161 lacs pertaining to the period April 2011 to September 2011 materialised and accounted during the current quarter.
- 7 On September 30, 2011, the Company has filed a Draft Letter of Offer (DLOF) with Securities and Exchange Board of India (SEBI) for the proposed Rights Issue of its equity shares aggregating to ₹1,100 lacs. The Company has incurred certain expenses in relation to said Rights Issue activity which have been accounted for as "Miscellaneous Expenditure (to the extent not written off or adjusted)". These expenses will be charged to the securities premium account proposed to be received from the Rights Issue of the equity shares of the Company.
- 8 Previous quarter / year figures have been regrouped wherever necessary.

By Order of the Board
For Neuland Laboratories Limited

Dr. D.R. Rao

Chairman & Managing Director

Place: Hyderabad

Date: February 10, 2012

Works : (i) Bonthapalli (V), Veerabhadraswamy Temple Road, Jinnaram (M). Medak Dist. 502 313, A.P., INDIA

(ii) Plot Nos. 92.93.94.257.258.259, IDA, Pashamylaram, Isnapur, Patancheru (M), Medak Dist. 502 319, A.P., INDIA